中国药业2016，Vol.25Issue(11)：4-6,7,4.
幽门螺杆菌根除治疗中联合用药研究进展
Research Progress of Combination Treatment in Helicobacter Pylori Eradication
摘要
Abstract
Helicobacter pylori (HP) is closely related to gastric cancer, and is an important factor of infecting chronic gastritis and pep-tic ulcer. Helicobacter pylori has been listed as a Class Ⅰ carcinogen by World Health Organization IARC. However, the gastric inflam-mation caused by Helicobacter pylori, as well as the malignant transformation mechanism of persistent inflammation of HP need study further. This paper briefly introduces the spread, pathogenesis and other basic information of Helicobacter pylori, describes the combination therapy of eradicating HP in detail. People all over the world have commonly infected with HP, especially in our country, most of the people have been infected with HP. Therefore, there is a urgent need to explore an ideal treatment for HP infection, which is of great significance. The common drugs for HP infection are divided into single drug and combined drugs, which are triple therapy and quadru-ple therapy based. Bigeminy therapy is a combine of proton pump inhibitors (PPIs) and amoxicillin. Triple therapy is either bismuth based, with 2 antibiotics, or PPIs with bismuth and 2 antibiotics. Quadruple therapy consists of PPIs, bismuth and 2 antibiotics. This arti-cle summarizes these commonly used treatments in recent years, and analyzes the advantages and disadvantages of them.关键词
幽门螺杆菌/致病机理/联合疗法/根除治疗/进展Key words
Helicobacter pylori/pathogenesis/combination therapy/eradication treatment/progress分类
医药卫生引用本文复制引用
王善春,李祎..幽门螺杆菌根除治疗中联合用药研究进展[J].中国药业,2016,25(11):4-6,7,4.基金项目
国家科技重大专项子任务，项目编号2014ZX09201001006003，2013ZX09201006。 （）
